Preclinical efficacy of Virulizin in human breast, ovarian and prostate tumor models.

Abstract

Virulizin is a novel biological response modifier (BRM) approved for the treatment of melanoma and is currently in a phase III clinical trial against advanced pancreatic cancer. The purpose of this study was to define the anti-cancer activity of Virulizin against a number of solid human tumors. The therapeutic effect of Virulizin was evaluated in mouse… (More)

Topics

  • Presentations referencing similar topics